Analyst consensus rating
Pacific Biosciences of California Analyst Rating: Buy
PACB is rated Buy by 6 analysts with a $2.29 target. As of 2026-08-24.
Direct answer
Pacific Biosciences of California's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $2.29.
Forecast evidence checked August 24, 2026.
Get free Pacific Biosciences of California email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.35
- Average price target
- $2.29
- High price target
- $3.00
- Low price target
- $1.25
- Low target gap
- -7.4%
- Target upside
- +69.8%
- High target gap
- +122.2%
- Target range width
- 129.6%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Pacific Biosciences of California?
Pacific Biosciences of California has a verified Buy consensus. The same dataset has an average price target of $2.29.
How far are Pacific Biosciences of California's low and high targets from the recorded price?
The low target implies -7.4%, while the high target implies +122.2%.
How many analysts are included in Pacific Biosciences of California's consensus?
The verified consensus includes 6 analysts.
How is Pacific Biosciences of California's target upside or downside calculated?
The average target of $2.29 is divided by the recorded price of $1.35, then one is subtracted to produce +69.8%. This does not guarantee a future return.
When was Pacific Biosciences of California's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.